3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Transitional Cell
16
Urinary Bladder Neoplasms
15
Carcinoma, Merkel Cell
10
Neoplasm Metastasis
8
Carcinoma, Renal Cell
8
Breast Neoplasms
8
Neoplasms
6
Triple Negative Breast Neoplasms
5
Melanoma
5
Ureteral Neoplasms
4
Stomach Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
4
Ovarian Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Urethral Neoplasms
3
Skin Neoplasms
3
Prostatic Neoplasms
3
Colorectal Neoplasms
3
Uterine Cervical Neoplasms
2
Small Cell Lung Carcinoma
2
Sarcoma
2
Neuroendocrine Tumors
2
Head and Neck Neoplasms
2
Endometrial Neoplasms
2
Carcinoma, Squamous Cell
2
Carcinoma, Hepatocellular
2
Uveal Melanoma
1
Urothelial Cancer
1
Turcot syndrome
1
Thymoma
1
Interventions
pembrolizumab
14
Nivolumab
11
Ipilimumab
10
cabozantinib
6
Axitinib
6
belzutifan
5
Radiosurgery
5
atezolizumab
4
Sunitinib
4
palbociclib
3
lenvatinib
3
Surveys and Questionnaires
3
Radiotherapy
3
Pluvicto
3
Everolimus
3
Blood Specimen Collection
3
Biopsy
3
zimberelimab
2
pazopanib
2
cemiplimab
2
Therapeutics
2
Methods
2
Magnetic Resonance Spectroscopy
2
Irinotecan
2
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
2
trebananib
1
toripalimab
1
tocilizumab
1
temsirolimus
1
spartalizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Kidney Neoplasms
×
avelumab
×
1 year
×
Clear all
NCT02684006
2025-07-30
JAVELIN Renal 101
Pfizer
Phase 3
Completed
886 enrolled
37 charts
1 FDA